Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweetsMarketScreener Strategies

AstraZeneca gets FDA breakthrough therapy label for asthma treatment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/07/2018 | 08:46am CET
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London

(Reuters) - AstraZeneca Plc and Amgen Inc said on Friday the U.S. Food and Drug Administration had granted a breakthrough therapy label for their drug to treat a type of severe asthma, potentially speeding up its development and regulatory review.

The drug, tezepelumab, is an injectable treatment that is expected to help a wider range of patients than existing asthma medicines like GlaxoSmithKline Nucala.

A breakthrough therapy status is designed to expedite the development and regulatory review of medicines that are intended to treat a serious condition and that have shown encouraging early clinical results.

A mid-stage trial in 2017 of 584 patients showed that tezepelumab reduced the annual rate of serious asthma attacks, known as exacerbations, by between 61 percent and 71 percent, depending on dose.

Tezepelumab is currently in late-stage trials.

The drug has shown promise in treating "a broad population of patients with severe asthma, including those ineligible for currently approved biologic therapies," said David Reese, executive vice president of Research and Development at U.S.-based Amgen.

(Reporting by Nivedita Balu in Bengaluru; Editing by Sai Sachin Ravikumar)

Stocks mentioned in the article
ChangeLast1st jan.
AMGEN 0.73% 193.7321 Delayed Quote.9.47%
ASTRAZENECA -1.79% 6204 Delayed Quote.23.35%
GLAXOSMITHKLINE -0.04% 1562 Delayed Quote.18.16%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN
04:00pAMGEN : Gets CHMP Positive Opinion to Expand Use of Blincyto
DJ
03:14pAMGEN : Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab)..
PU
11/15AMGEN : Ex-dividend day for
FA
11/12AMGEN : Presents Results Highlighting The Long-Term Safety And Efficacy Of Repat..
PU
11/12AMGEN : Foundation Pledges $500,000 In Relief To Victims Of Ventura And Los Ange..
PR
11/07AMGEN : Announces Presentation Of Research Reinforcing The Long-Term Safety And ..
AQ
11/07AMGEN : Coherus` newly minted Neulasta biosim steps up pressure on Amgen
AQ
11/06BIOCON : Coherus looks to disrupt Amgens $4B Neulasta franchise as analysts look..
AQ
11/06AMGEN : announces presentation of new clinical data showcasing early oncology pi..
AQ
11/05AMGEN : Announces Presentation Of Research Reinforcing The Long-Term Safety And ..
PU
More news
News from SeekingAlpha
10:47aBargain hunters move back into biotech 
10:21aEuropean advisory group reverses position, now backs Amgen's Blincyto for typ.. 
11/15CANCER RESEARCH HIGHLIGHT : RedHill Biopharma Sets Up Continued Invasion Into Ca.. 
11/15CytomX' Translational Data On CX-072 Point Towards A Positive Readout From CX.. 
11/15Biotech Giant Should Deliver Mid-Teens Total Returns 
Financials ($)
Sales 2018 23 363 M
EBIT 2018 11 785 M
Net income 2018 8 565 M
Finance 2018 2 166 M
Yield 2018 2,71%
P/E ratio 2018 15,21
P/E ratio 2019 14,58
EV / Sales 2018 5,16x
EV / Sales 2019 5,03x
Capitalization 123 B
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 204 $
Spread / Average Target 6,1%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline CFO, Chief Accounting Officer & Executive VP
David M. Reese Executive Vice President-Research & Development
Frank C. Herringer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN9.47%122 633
JOHNSON & JOHNSON3.24%387 546
PFIZER18.47%250 618
NOVARTIS6.19%221 937
ROCHE HOLDING LTD.0.39%212 046
MERCK AND COMPANY33.00%194 612